VolitionRx Limited logo
VolitionRx Limited VNRX
$ 0.21 12.86%

Quarterly report 2025-Q3
added 11-13-2025

report update icon

VolitionRx Limited Income Statement 2011-2026 | VNRX

Annual Income Statement VolitionRx Limited

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

54.8 M 58.1 M 89.1 M 157 M 200 M 185 M 79.7 M 92.6 M 107 M 66.8 M 67.2 M 27.1 M 23.4 M -

Shares

96.1 M 81.9 M 57.9 M 53.8 M 43.4 M 39.2 M 31.4 M 26.4 M 23 M 17.7 M 13.4 M 10.8 M 9.36 M -

Historical Prices

0.57 0.71 1.54 2.92 4.08 3.44 2.95 3.06 4.42 3.66 4.11 2.75 2.5 -

Net Income

-27.3 M -35.7 M -30.6 M -27 M - -16.1 M -18 M -14.8 M -11.9 M -9.53 M -8.21 M -3.71 M - -13 K

Revenue

1.23 M 775 K 306 K 90 K - 17.1 K - - - - - - - -

Operating Income

-27 M -36 M -31.8 M -28.3 M -21.2 M -16 M -17.9 M -14.7 M -12.4 M -10 M -5.95 M -4.58 M -4.08 M -2.61 M

Interest Expense

-233 K 311 K - - 130 K 127 K -111 K 73.1 K 20.4 K -15.7 K 14.8 K - - -

EBITDA

-25.9 M -34.8 M -30.8 M -27.4 M - -15.4 M -17.3 M -14.2 M -12.1 M -9.77 M -5.81 M -4.18 M 70 K -13 K

Operating Expenses

28.3 M 36.8 M 32.1 M 28.4 M - 15.9 M 17.9 M 15 M 11.9 M 9.86 M 5.81 M 3.36 M 4.14 M -

General and Administrative Expenses

8.49 M 10.4 M 10.2 M 11.7 M 5.47 M 4.52 M 5.78 M 5.36 M 5.43 M 3.9 M 1.91 M 1.72 M 1.3 M -

All numbers in USD currency

Quarterly Income Statement VolitionRx Limited

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

110 M 104 M 101 M 96.1 M 92.4 M 82.9 M 82.1 M 81.9 M 78.3 M 78.1 M 63.1 M 57.9 M 57.5 M 53.8 M 53.8 M 53.8 M 53.2 M 52.9 M 50.9 M 48.6 M 47 M 43.4 M 41.2 M 41.1 M 39.9 M 38.9 M 36.2 M 35.3 M 32.8 M 30 M 27.3 M 26.5 M 26.5 M 26.4 M 26.1 M 26.1 M 23.5 M 23.4 M 19.3 M 18.8 M 18 M 17.9 M 16.5 M 14.7 M 13.5 M 13.4 M 12.2 M 11.7 M 11.7 M 11.7 M 11.7 M 10.2 M 10.2 M 10.2 M 10.2 M 8.65 M 8.65 M 8.65 M 8.65 M

Net Income

-5.38 M -6.28 M -5.42 M - -5.87 M -7.06 M -8.47 M - -8.45 M -9.55 M -8.87 M - -7.81 M -7.73 M -7.72 M - -7.18 M -5.57 M -6.13 M - -4.34 M -5.04 M -5.86 M - -4.18 M -4.16 M -4.2 M - -4.48 M -4.59 M -4.65 M - -3.89 M -3.46 M -3.35 M - -3.48 M -2.95 M -2.49 M - -2.96 M -1.87 M -2.01 M - -5.89 M 817 K -2.19 M - -926 K -1.05 M -908 K - -2.61 M -931 K -802 K - -1.69 M -640 K -335 K

Revenue

627 K 407 K 246 K - 475 K 396 K 172 K - 165 K 216 K 150 K - 32.7 K 39.8 K 114 K - 25.5 K 24.8 K 25.5 K - 575 5.19 K 544 - 17.1 K - - - - - - - - - - - - - - - - - - - 14.8 K - - - - - - - 27.6 K 11.7 K 15.7 K - - - -

Operating Income

-5.1 M -6.3 M -5.52 M - -5.87 M -6.99 M -8.38 M - -8.65 M -9.55 M -9.05 M - -7.99 M -8.1 M -7.68 M - -7.56 M -5.9 M -6.09 M - -4.5 M -5.21 M -5.87 M - -4.18 M -4.15 M -3.99 M - -4.45 M -4.57 M -4.63 M - -3.88 M -3.44 M -3.34 M - -3.48 M -2.98 M -2.49 M - -2.97 M -2.02 M -2.35 M - -1.76 M -1.05 M -1.24 M - -926 K -1.05 M -908 K - -873 K -931 K -802 K - - - -

Interest Expense

-309 K -16.3 K 45.1 K - 129 -69.8 K - - - - - - - - 41 K - 38.8 K 39.7 K 42.2 K - 34.7 K 22.6 K 33.8 K - 32.3 K 33.1 K -30.1 K - -29.1 K 26.6 K 23 K - 17.6 K 20.4 K 12.2 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -5.27 M - - - -8.12 M - - - -8.77 M - -7.31 M -7.65 M -7.45 M - -6.85 M -5.43 M -5.86 M - -3.98 M -4.85 M -5.69 M - -3.67 M -3.81 M -3.82 M - -3.97 M -4.25 M -4.47 M - -3.5 M -3.22 M -3.25 M - -3.25 M -2.82 M -2.42 M - -2.8 M -1.93 M -2.31 M - -1.66 M -987 K -1.21 M - -817 K -975 K -871 K - -769 K -862 K -769 K - 77.6 K 47.6 K 23.9 K

Operating Expenses

5.73 M 6.7 M 5.77 M - 6.34 M 7.39 M 8.56 M - 8.82 M 9.77 M 9.19 M - 8.03 M 8.14 M 7.79 M - 7.59 M 5.93 M 6.11 M - 4.5 M 5.22 M 5.87 M - 4.19 M 4.15 M 3.99 M - 4.45 M 4.57 M 4.63 M - 3.88 M 3.44 M 3.34 M - 3.48 M 2.98 M 2.49 M - 2.97 M 2.02 M 2.35 M - 1.78 M 1.05 M 1.24 M - 926 K 1.05 M 908 K - 900 K 943 K 817 K - - 640 K 335 K

General and Administrative Expenses

2.48 M 2.94 M 2.24 M - 1.82 M 2.28 M 2.25 M - 2.6 M 2.64 M 2.58 M - 2.76 M 3.09 M 2.6 M - 3.14 M 2.43 M 1.81 M - 1.08 M 1.51 M 1.7 M - 1.35 M 1.44 M 1.23 M - 1.45 M 1.64 M 1.84 M - 1.56 M 1.43 M 1.4 M - 164 K 166 K 228 K - 141 K 122 K 248 K - 129 K 51.8 K 68.9 K - 68 K 123 K 51.6 K - 48.2 K 149 K 38 K - 54.7 K 45.1 K 49.9 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company VolitionRx Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.71 0.73 % $ 7.5 M usaUSA
Illumina Illumina
ILMN
$ 123.79 -0.43 % $ 19.7 B usaUSA
Biomerica Biomerica
BMRA
$ 2.13 -2.74 % $ 4.89 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 25.75 3.0 % $ 715 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
NeoGenomics NeoGenomics
NEO
$ 8.1 1.76 % $ 1.04 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 104.91 - $ 19.8 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.51 1.1 % $ 392 M usaUSA
Natera Natera
NTRA
$ 200.09 2.46 % $ 19.7 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 129 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.15 2.68 % $ 798 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Personalis Personalis
PSNL
$ 7.61 4.82 % $ 451 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 158.0 2.86 % $ 7.83 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 166.96 0.54 % $ 28.7 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 75.73 -0.92 % $ 5.11 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 578.51 0.22 % $ 46.5 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.46 26.96 % $ 1.86 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 456.93 0.98 % $ 13.2 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.62 2.16 % $ 276 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 13.88 2.81 % $ 3.94 B usaUSA
Agilent Technologies Agilent Technologies
A
$ 112.02 0.65 % $ 34.1 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 100.35 0.65 % $ 8.28 B irlandaIrlanda
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 31.72 -4.52 % $ 1.61 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.5 -6.13 % $ 29.9 M israelIsrael
Guardant Health Guardant Health
GH
$ 84.9 -0.33 % $ 10.6 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.66 1.75 % $ 432 M usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Neuronetics Neuronetics
STIM
$ 1.6 10.34 % $ 106 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 239.07 2.87 % $ 25.5 B schweizSchweiz
CareDx, Inc CareDx, Inc
CDNA
$ 17.56 2.39 % $ 936 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 3.48 0.87 % $ 1.87 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 478.12 0.79 % $ 180 B usaUSA
Celcuity Celcuity
CELC
$ 106.75 0.67 % $ 4.21 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 264.42 0.54 % $ 22 B usaUSA